Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.56 |
| ▸ | XDH | P47989 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31120448 | 1.00 | LCK (0.67) | LCKCA12CA1CA2CA7 | |
| SCHEMBL31525443 | 0.87 | LCK (0.58) | LCKCA12CA1CA2CA7 | |
| SCHEMBL31203305 | 0.87 | LCK (0.58) | LCKCA12CA1CA2CA7 | |
| SCHEMBL2810717 | 0.87 | LCK (0.58) | LCKCA12CA1CA2CA7 | |
| SCHEMBL6412058 | 0.83 | LCK (0.58) | LCKCA12CA1CA2CA7 | |
| SCHEMBL30213808 | 0.83 | LCK (0.58) | LCKCA12CA1CA2CA7 | |
| SCHEMBL69179 | 0.83 | LCK (0.58) | LCKCA12CA1CA2CA7 | |
| SCHEMBL27364085 | 0.83 | LCK (0.66) | LCKCA12CA1CA2CA7 | |
| SCHEMBL16287769 | 0.82 | LCK (0.56) | LCKCA12CA1CA2CA7 | |
| SCHEMBL5762353 | 0.82 | LCK (0.56) | LCKCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688730-A1 | SYNTHESIS OF A HIPPO-YAP PATHWAY MODULATOR AND A POLYMORPH THEREOF | Vivace Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3956033-B1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024206300-A1 | SYNTHESIS OF A HIPPO-YAP PATHWAY MODULATOR AND A POLYMORPH THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-12103902-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-114072207-B | Bicyclic compounds | 维瓦斯治疗公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240025913-A1 | TERTIARY CARBOXAMIDE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025913-A1 | TERTIARY CARBOXAMIDE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025913-A1 | TERTIARY CARBOXAMIDE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20220298102-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220298102-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-100453529-C | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2009-01-21 | — | — | CN | disclosed |
| CN-101177385-A | Aryl sulfonic acid amides and analogues as well as its purpose in curing neural degeneration disease | BAYER AG (DE) | 2008-05-14 | — | — | CN | disclosed |
| CN-100371318-C | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2008-02-27 | — | — | CN | disclosed |
| CN-1754873-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2006-04-05 | — | — | CN | disclosed |
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| CN-1253545-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2000-05-17 | — | — | CN | disclosed |
| US-5298593-A | Polymerization of ester monomer, aromatic dicarboxylic acid, and oxyaromatic carboxylic acid | MITSUBISHI PETROCHEMICAL COMPANY, LTD. (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0520428-A2 | Method of producing thermotropic liquid crystalline polyester | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298102-A1 | BICYCLIC COMPOUNDS | YAP1, TEAD2, TEAD3 | LCK 901/4885CA12 4576/4885CA1 4630/4885 |
| US-20240025913-A1 | TERTIARY CARBOXAMIDE COMPOUNDS | YAP1, TFAM, PC | LCK 902/4885CA12 4580/4885CA1 4662/4885 |
| US-12103902-B2 | Bicyclic compounds | YAP1, TEAD2, TEAD3 | LCK 632/4885CA12 4686/4885CA1 4809/4885 |
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | LCK 4553/4885CA12 3284/4885CA1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.